Short Interest in Affimed (NASDAQ:AFMD) Rises By 38.5%

Affimed (NASDAQ:AFMD) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 846,900 shares, an increase of 38.5% from the November 30th total of 611,400 shares. Currently, 6.5% of the shares of the company are sold short. Based on an average trading volume of 253,700 shares, the days-to-cover ratio is presently 3.3 days.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AFMD. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Wells Fargo & Company dropped their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Stifel Nicolaus decreased their price target on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Hedge Funds Weigh In On Affimed

Several institutional investors have recently bought and sold shares of AFMD. Point72 Asset Management L.P. lifted its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Jane Street Group LLC bought a new stake in Affimed in the 3rd quarter valued at $44,000. Intellectus Partners LLC increased its holdings in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the period. Choreo LLC acquired a new position in shares of Affimed during the second quarter valued at about $54,000. Finally, FMR LLC lifted its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the period. 30.82% of the stock is currently owned by institutional investors.

Affimed Trading Down 3.1 %

NASDAQ AFMD traded down $0.04 during trading on Monday, reaching $1.25. The company’s stock had a trading volume of 81,815 shares, compared to its average volume of 289,498. The business has a 50-day moving average price of $2.72 and a 200-day moving average price of $3.84. Affimed has a 1-year low of $1.14 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.